The platform’s functionality is adept at monitoring amyloid-related imaging abnormalities in those undergoing anti-amyloid treatments. Credit: Triff / Shutterstock.

Cortechs.ai has announced a strategic partnership with the Alzheimer’s Network for Treatment and Diagnostics (ALZ-NET) aimed at improving the quality of care for Alzheimer’s disease patients through imaging.

This alliance will integrate Cortechs.ai’s NeuroQuant for ARIA imaging platform with the real-world data network of ALZ-NET to support clinical decision-making and care delivery.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Under this collaboration, ALZ-NET sites will receive discounted access to the imaging platform across various clinical settings.

This platform segments, quantifies and offers longitudinal tracking of fluid-attenuated inversion recovery (FLAIR) and T2-weighted gradient-echo (T2GRE)/susceptibility-weighted imaging (SWI) lesions.

Its functionality is particularly adept at monitoring amyloid-related imaging abnormalities (ARIA) such as ARIA-E and ARIA-H in those undergoing anti-amyloid treatments.

Cortechs.ai noted that NeuroQuant for ARIA’s capabilities extend to both two-dimensional (2D) and 3D FLAIR sequences, ensuring compatibility with imaging protocols.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

This clinically validated solution can identify and quantify cerebral microbleeds and superficial siderosis on T2GRE and SWI scans and presents an AI-assisted tool for monitoring patients with Alzheimer’s.

Cortechs.ai CEO Kyle Frye said: “Our collaboration with ALZ-NET represents a shared commitment to using data and technology to improve how we care for people with dementia.

“With NeuroQuant for ARIA, we’re giving clinicians the tools they need to make smarter, safer decisions, and by connecting with ALZ-NET’s powerful data network, we can collectively advance treatment practices for the entire field.” 

Sponsored by the Alzheimer’s Association and managed by the American College of Radiology, ALZ-NET gathers clinical and imaging data from individuals tested for or treated with Alzheimer’s therapies that are approved by the US Food and Drug Administration (FDA).

The network’s goal is to gather longitudinal, real-world data to inform the long-term efficacy and safety of treatments for the disease.

Cortechs.ai develops medical device software that aids in the quantitative analysis of magnetic resonance (MR) imaging.

Medical Device Network Excellence Awards - Have you nominated?

Nominations are now open for the prestigious Medical Device Network Excellence Awards - one of the industry's most recognised programmes celebrating innovation, leadership, and impact. This is your chance to showcase your achievements, highlight industry advancements, and gain global recognition. Don't miss the opportunity to be honoured among the best - submit your nomination today!

Nominate Now